The technology integrates three sequential processes in a single automated system to capture clinically significant CTCs. First, after whole blood samples have been labeled with magnetic beads, the system separates nucleated cells, including CTCs and white blood cells, from red blood cells and platelets with minimal cell loss. Next, the system aligns nucleated cells in a single file within a sorting channel. Finally, the magnetically tagged cells are deflected into a collection channel for identification. These three integrated functions replace the need for separate cell lysis (break down), centrifugation and sorting steps.
About Circulating Tumor Cells
Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.
About Veridex, LLCVeridex, LLC, a Johnson & Johnson company, is an organization dedicated to providing physicians with high-value diagnostic oncology products. Veridex's in vitro diagnostic products may significantly benefit patients by helping physicians make more informed decisions that enable better patient care. Veridex's Clinical Research Solutions provide tools and services that may be used for the selection, identification and enumeration of targeted rare cells in peripheral blood for the identification of biomarkers, aiding scientists in their search for new, targeted therapies. For more information, visit www.veridex.com. Media inquiries for Massachusetts General Hospital can be directed to: Sue McGreevey, email@example.com, 617-724-2764 Katie Marquedant, firstname.lastname@example.org, 617-724-6423 Media Inquiries:Janssen Kellie McLaughlinPhone: 1-908-927-7477 Mobile: 1-609-468-8356 Investor Relations: Johnson & Johnson Stan PanasewiczPhone: 1-732-524-2524 Louise MehrotraPhone: 1-732-524-6491 SOURCE Veridex, LLC